Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BladeRock Capital
Bethesda, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
BladeRock Capital was a U.S.-based investment firm focused on life science and healthcare companies rather than a drug developer or operating biopharma company. Public references describe it as the predecessor firm to V2M Capital, founded in 2005 by J. Misha Petkevich and focused on investing in life science companies, including public healthcare equities. Available evidence suggests BladeRock Capital functioned as a specialized healthcare investment manager/hedge fund rather than a therapeutics company with an internal R&D pipeline. It appears to no longer operate under the BladeRock Capital name, having been succeeded or rebranded as V2M Capital.
- Industry
- Investors
Beyond the preview
Go deeper on BladeRock Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BladeRock Capital.